amlodipine has been researched along with Angor Pectoris in 124 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-nine hypertensive patients with associated coronary artery disease (stable angina pectoris) and isolated diastolic dysfunction were randomized to receive amlodipine (30 patients) or lacidipine (29 patients) for 4 weeks." | 9.11 | Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. ( Brazdzionyte, J; Jurkevicus, R; Zabiela, V; Zaliunas, R, 2005) |
| "To estimate the influence of therapy with amlodipine (A) or lacidipine (L) on heart rate variability (HRV) time and frequency domain parameters in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction." | 9.11 | Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction. ( Brazdzionyte, J; Jurkevicius, R; Zabiela, V; Zaliūnas, R, 2005) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 9.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "To compare the effects of amlodipine and slow release metoprolol on subjective symptoms and signs of ischaemia during bicycle ergometric exercise tests in patients with stable angina pectoris." | 9.09 | Amlodipine versus slow release metoprolol in the treatment of stable exertional angina pectoris (AMSA). ( Midtbø, K; Mølstad, P, 2000) |
| "The study was undertaken to evaluate whether the effect of combined amlodipine and atenolol therapy on patients with stable angina pectoris and with ST-depression during exercise testing and 48-h ambulatory electrocardiographic monitoring is superior to that of either agent given alone." | 9.09 | Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. ( Ekdahl, S; Karlson, BW; Pehrsson, SK; Persson, S; Ringqvist, I; Ulvenstam, G, 2000) |
| "This double-blind study compared the efficacy and safety of once daily amlodipine (5-10 mg/day) vs twice daily nifedipine (40-80 mg/day) in 244 patients with chronic stable angina pectoris." | 9.09 | [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. ( Kupper, W; Sauerbrey-Wullkopf, N, 2001) |
| "A multicenter, double-blind study was performed to compare the efficacy and safety of the calcium antagonists, amlodipine and diltiazem controlled release (CR), in patients with stable angina pectoris." | 9.08 | A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group. ( van Kesteren, HA; Withagen, AJ, 1998) |
| "The purpose of the study was to compare the antianginal and hypotensive efficacy and tolerability of 8 weeks of treatment with amlodipine taken once daily and nifedipine taken twice daily in patients with stable exertional angina pectoris and mild-to-moderate hypertension." | 9.08 | [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. ( Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997) |
| "A multicenter, double-blind study was performed to compare the antianginal efficacy and safety of the new dihydropyridine calcium antagonist amlodipine with the benzothiazepine calcium antagonist diltiazem in patients with stable exertional angina pectoris." | 9.07 | An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. ( Barth, J; Bernink, PJ; de Weerd, P; Enthoven, R; Haagen, FD; Holwerda, NJ; Klomps, HC; Remme, WJ; ten, CF, 1991) |
| "An interim analysis of patient compliance is reported in 234 hypertension outpatients who were entered into a large-scale, open, crossover, comparative study between a new-generation calcium antagonist, amlodipine (5 mg, once daily), and nifedipine SR (20 mg, twice daily)." | 9.07 | Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient ( Detry, JM, 1994) |
| "The acute hemodynamic and electrophysiologic effects of intravenous amlodipine (2 x 10 mg), administered either alone or on a background of beta-blocker therapy, were studied in 25 patients with angina pectoris." | 9.07 | Evaluation of the acute hemodynamic and electrophysiologic effects of intravenous amlodipine alone and in combination with a beta-blocker in patients with angina pectoris. ( Epstein, AE; Kay, GN; Plumb, V; Vetrovec, GW, 1993) |
| "Amlodipine 10 mg was evaluated for additional anti-ischaemic and anti-anginal efficacy in 14 patients pre-treated with a beta-blocker who had documented coronary artery disease, stable angina pectoris, and > or = 2 mm of exercise-induced ST segment depression." | 9.07 | Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. ( Beyerle, A; Lehmann, G; Reiniger, G; Rudolph, W, 1993) |
| "The effects of 5 and 10 mg of amlodipine and of placebo were compared in 21 patients with stable angina pectoris and multivessel coronary artery disease." | 9.07 | Amlodipine in patients with stable angina pectoris treated with nitrates and beta-blockers. The influence on exercise tolerance, systolic and diastolic functions of the left ventricle. ( Julínek, J; Meluzín, J; Novák, M; Simek, P; Spinarová, L; Stejfa, M; Toman, J; Zeman, K, 1992) |
| "This study evaluated the safety, antianginal and antiischemic effects of amlodipine, a dihydropyridine calcium antagonist, in patients with chronic stable angina pectoris." | 9.06 | Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. ( Glasser, SP; West, TW, 1988) |
| " In comparison with other antianginal drugs, once-daily amlodipine at a dosage range of 5-10 mg demonstrated antianginal activity comparable to thrice-daily diltiazem and once-daily nadolol." | 7.77 | Usefulness of amlodipine for angina pectoris. ( Taylor, SH, 1994) |
| "Possibilities of secondary prevention of reperfusion syndrome with amlodipine was assessed in 46 patients (39 with class III-IV angina after myocardial infarction and 7 with non ST elevation acute coronary syndrome)." | 7.72 | [Reperfusion syndrome after direct myocardial revascularization on beating heart in patients with ischemic heart disease. Possibilities of prevention with amlodipine]. ( Akhmedov, ShD; Dzhavadova, GK; Kandinskiĭ, ML; Tepliakov, AT; Vesnina, ZhV, 2003) |
| " The most frequent adverse events were visual symptoms and sinus bradycardia with ivabradine (0." | 6.73 | Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. ( Ford, I; Fox, KM; Ruzyllo, W; Tendera, M, 2007) |
| "This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 6.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
| "Anginal patients who remain symptomatic despite optimally dosed beta blockade may also be given dihydropyridine calcium antagonists." | 6.69 | Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. ( Bernink, PJ; Bouwens, LH; Dunselman, PH; Herweijer, AH; Holwerda, KJ; van Kempen, LH, 1998) |
| " From these results, the optimal dosage of amlodipine in the treatment of angina pectoris is 10 mg for the initial 3 days followed by 5 mg thereafter." | 6.68 | Clinical evaluation of serum amlodipine level in patients with angina pectoris. ( Inomata, T; Izumi, T; Miyakita, Y; Nagatomo, T; Ochiai, Y; Qu, YL; Shiba, M; Shibata, A; Washizuka, T; Watanabe, K, 1996) |
| "Mibefradil-treated patients showed greater decreases in heart rate and the rate-pressure product at each stage of the ETT than patients treated with amlodipine or diltiazem SR." | 6.68 | Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. ( Davies, GJ; Kobrin, I; Tzivoni, D, 1997) |
| "Amlodipine was well tolerated and no patients were withdrawn due to adverse events or laboratory abnormalities." | 6.67 | A double-blind, placebo-controlled, parallel dose-response study of amlodipine in stable exertional angina pectoris. ( Cocco, G; Jackson, N; Lee, P; Taylor, SH, 1991) |
| "The amlodipine dose was adjusted to 10 mg daily after 2 weeks if angina attacks were not abolished." | 6.67 | A 6-week double-blind comparison of amlodipine and placebo in patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy. ( Cocco, G; Fitscha, P; Klein, W; Meisner, W; Mitrovic, V; Neuss, H; Prager, G; Schlepper, M, 1991) |
| "Amlodipine has significant anti-anginal efficacy." | 6.67 | A double-blind dose-response study of amlodipine in patients with stable angina pectoris. ( Alfiero, R; Cocco, G, 1991) |
| "Mibefradil is a recently developed calcium antagonist with a unique chemical structure, pharmacologic profile, and mode of action." | 6.40 | Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris. ( Massie, BM, 1998) |
| "Stable patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks." | 5.12 | Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. ( Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006) |
| "Amlodipine, a dihydropyridine calcium channel antagonist, is prescribed for the management of angina and hypertension." | 5.12 | Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ( Ha, MC; Kang, SW; Kim, JS; Kim, KA; Lee, GH; Lee, KR; Lee, OJ; Park, JY; Park, PW; Ryu, JH, 2006) |
| "To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension." | 5.11 | Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. ( Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA, 2004) |
| "To estimate the influence of therapy with amlodipine (A) or lacidipine (L) on heart rate variability (HRV) time and frequency domain parameters in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction." | 5.11 | Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction. ( Brazdzionyte, J; Jurkevicius, R; Zabiela, V; Zaliūnas, R, 2005) |
| "Fifty-nine hypertensive patients with associated coronary artery disease (stable angina pectoris) and isolated diastolic dysfunction were randomized to receive amlodipine (30 patients) or lacidipine (29 patients) for 4 weeks." | 5.11 | Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. ( Brazdzionyte, J; Jurkevicus, R; Zabiela, V; Zaliunas, R, 2005) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 5.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "This double-blind study compared the efficacy and safety of once daily amlodipine (5-10 mg/day) vs twice daily nifedipine (40-80 mg/day) in 244 patients with chronic stable angina pectoris." | 5.09 | [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. ( Kupper, W; Sauerbrey-Wullkopf, N, 2001) |
| "Four hundred seventy-five patients with angina pectoris were randomized to double-blind treatment with PPR (physiological pattern release) verapamil hydrochloride, amlodipine besylate, amlodipineatenolol combination, or placebo." | 5.09 | Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. ( Anderson, R; Hollenberg, NK; Williams, GH, 2000) |
| "The Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES) is a multicentre, double-blind, placebo controlled restenosis trial investigating the effect of amlodipine on angiographic and clinical endpoints in patients undergoing routine percutaneous transluminal coronary angioplasty (PTCA) for stable angina pectoris." | 5.09 | Results and clinical implications of the CAPARES trial. ( Jorgensen, B; Thaulow, E, 2000) |
| "The study was undertaken to evaluate whether the effect of combined amlodipine and atenolol therapy on patients with stable angina pectoris and with ST-depression during exercise testing and 48-h ambulatory electrocardiographic monitoring is superior to that of either agent given alone." | 5.09 | Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. ( Ekdahl, S; Karlson, BW; Pehrsson, SK; Persson, S; Ringqvist, I; Ulvenstam, G, 2000) |
| "To compare the effects of amlodipine and slow release metoprolol on subjective symptoms and signs of ischaemia during bicycle ergometric exercise tests in patients with stable angina pectoris." | 5.09 | Amlodipine versus slow release metoprolol in the treatment of stable exertional angina pectoris (AMSA). ( Midtbø, K; Mølstad, P, 2000) |
| "The efficacy and safety of amlodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study." | 5.08 | Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. ( Awan, N; Bommer, W; Ezekowitz, MD; Grossman, W; Hossack, K; Kostuk, W; Mehta, JL; Thadani, U; Weidler, DJ, 1995) |
| "A multicenter, double-blind study was performed to compare the efficacy and safety of the calcium antagonists, amlodipine and diltiazem controlled release (CR), in patients with stable angina pectoris." | 5.08 | A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group. ( van Kesteren, HA; Withagen, AJ, 1998) |
| "The safety and tolerability of mibefradil, a selective T-type calcium channel antagonist, were evaluated in 3,430 patients with essential hypertension and chronic stable angina pectoris treated in 15 double-blind placebo and active-controlled clinical trials and 2 open-label, long-term safety studies." | 5.08 | Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. ( Charlon, V; Kobrin, I; Lindberg, E; Pordy, R, 1997) |
| "Three hundred nine patients with coronary artery disease, stable angina pectoris, and positive exercise tests were randomized to receive mibefradil (50, 100, or 150 mg), amlodipine (10 mg), or placebo." | 5.08 | Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. ( Braat, S; Kadr, H; Kobrin, I; Ramires, JA; Rutsch, W; Tzivoni, D, 1997) |
| "The purpose of the study was to compare the antianginal and hypotensive efficacy and tolerability of 8 weeks of treatment with amlodipine taken once daily and nifedipine taken twice daily in patients with stable exertional angina pectoris and mild-to-moderate hypertension." | 5.08 | [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. ( Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997) |
| "A multicenter, double-blind study was performed to compare the antianginal efficacy and safety of the new dihydropyridine calcium antagonist amlodipine with the benzothiazepine calcium antagonist diltiazem in patients with stable exertional angina pectoris." | 5.07 | An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. ( Barth, J; Bernink, PJ; de Weerd, P; Enthoven, R; Haagen, FD; Holwerda, NJ; Klomps, HC; Remme, WJ; ten, CF, 1991) |
| "The acute hemodynamic and electrophysiologic effects of intravenous amlodipine (2 x 10 mg), administered either alone or on a background of beta-blocker therapy, were studied in 25 patients with angina pectoris." | 5.07 | Evaluation of the acute hemodynamic and electrophysiologic effects of intravenous amlodipine alone and in combination with a beta-blocker in patients with angina pectoris. ( Epstein, AE; Kay, GN; Plumb, V; Vetrovec, GW, 1993) |
| "Amlodipine 10 mg was evaluated for additional anti-ischaemic and anti-anginal efficacy in 14 patients pre-treated with a beta-blocker who had documented coronary artery disease, stable angina pectoris, and > or = 2 mm of exercise-induced ST segment depression." | 5.07 | Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. ( Beyerle, A; Lehmann, G; Reiniger, G; Rudolph, W, 1993) |
| " In this study, the safety and efficacy of a new generation dihydropyridine calcium antagonist, amlodipine (5-10 mg once daily) were evaluated in patients with chronic, stable angina pectoris." | 5.07 | A double-blind evaluation of amlodipine in patients with chronic, stable angina: sustained efficacy and lack of "withdrawal phenomenon" upon abrupt discontinuation. ( Lopez, LM; Mehta, JL, 1994) |
| "Once-daily administration of amlodipine is a highly effective treatment for patients with angina pectoris." | 5.07 | Amlodipine in post-infarction angina. ( Taylor, SH, 1992) |
| "The effects of 5 and 10 mg of amlodipine and of placebo were compared in 21 patients with stable angina pectoris and multivessel coronary artery disease." | 5.07 | Amlodipine in patients with stable angina pectoris treated with nitrates and beta-blockers. The influence on exercise tolerance, systolic and diastolic functions of the left ventricle. ( Julínek, J; Meluzín, J; Novák, M; Simek, P; Spinarová, L; Stejfa, M; Toman, J; Zeman, K, 1992) |
| "An interim analysis of patient compliance is reported in 234 hypertension outpatients who were entered into a large-scale, open, crossover, comparative study between a new-generation calcium antagonist, amlodipine (5 mg, once daily), and nifedipine SR (20 mg, twice daily)." | 5.07 | Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient ( Detry, JM, 1994) |
| "Amlodipine, a potent long-acting dihydropyridine calcium antagonist, was compared with placebo in a parallel, randomized, double-blind study in 134 patients with chronic stable angina pectoris maintained on beta-adrenergic blocking agents." | 5.07 | Amlodipine combined with beta blockade for chronic angina: results of a multicenter, placebo-controlled, randomized double-blind study. ( Awan, NA; Bamrah, VS; Barry, W; Bennett, T; Canosa, FL; DiBianco, R; Glasser, SP; Kawanishi, DT; Schoomaker, FW; Singh, JB, 1992) |
| "The utility of using an endurance test as well as a maximal exercise test to assess the effect of amlodipine, a dihydropyridine calcium antagonist, was evaluated in 16 patients with angina pectoris." | 5.06 | Endurance testing for evaluation of antianginal therapy with amlodipine, a calcium channel blocking agent. ( Harris, M; Hossack, KF; Kinnard, DR, 1988) |
| "The haemodynamic dose-response effects of a new long-acting slow-calcium channel blocking agent, amlodipine were evaluated in 20 patients with angiographically confirmed coronary heart disease." | 5.06 | A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease. ( Frais, MA; Jackson, NC; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1986) |
| "The hemodynamic effects and antianginal efficacy of 10 mg amlodipine administered intravenously were assessed for 45 minutes in 18 subjects with stable angina pectoris." | 5.06 | Pharmacodynamics of amlodipine: hemodynamic effects and antianginal efficacy after atrial pacing. ( Grant, P; Gupta, S; Hillis, WS; Hogg, KJ; Hornung, RS; Singh, SP, 1989) |
| "This study evaluated the safety, antianginal and antiischemic effects of amlodipine, a dihydropyridine calcium antagonist, in patients with chronic stable angina pectoris." | 5.06 | Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. ( Glasser, SP; West, TW, 1988) |
| "To review the efficacy and safety data of amlodipine and the angiotensin-receptor blockers (ARBs), focusing on heart failure, angina, percutaneous coronary intervention (PCI), and renal protection." | 4.81 | Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications. ( Kalus, JS; White, CM, 2002) |
| "Mibefradil was found to be well tolerated and safe; this held true for patients on chronic anti-anginal background therapy." | 3.79 | Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist. ( Bieska, G; Charlon, V; Kobrin, I; Lindberg, E; Pordy, R, 1998) |
| " In comparison with other antianginal drugs, once-daily amlodipine at a dosage range of 5-10 mg demonstrated antianginal activity comparable to thrice-daily diltiazem and once-daily nadolol." | 3.77 | Usefulness of amlodipine for angina pectoris. ( Taylor, SH, 1994) |
| "To examine the association between hospitalization for acute coronary syndromes and treatment with amlodipine or extended-release nifedipine in patients 65 years of age and older." | 3.74 | Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study. ( Bucci, C; Juurlink, DN; Mamdani, MM; Tu, JV, 2008) |
| "Possibilities of secondary prevention of reperfusion syndrome with amlodipine was assessed in 46 patients (39 with class III-IV angina after myocardial infarction and 7 with non ST elevation acute coronary syndrome)." | 3.72 | [Reperfusion syndrome after direct myocardial revascularization on beating heart in patients with ischemic heart disease. Possibilities of prevention with amlodipine]. ( Akhmedov, ShD; Dzhavadova, GK; Kandinskiĭ, ML; Tepliakov, AT; Vesnina, ZhV, 2003) |
| "Patients with stable angina pectoris received an intravenous bolus injection of 10 mg amlodipine followed by a second 10-mg bolus, 30 min later, if no haemodynamic compromise occurred." | 3.68 | Haemodynamic and electrophysiological effects of amlodipine, a new long-acting calcium antagonist. ( Dailey, S; Epstein, A; Kay, G; Plumb, V; Vetrovec, GW, 1991) |
| "The anti-anginal efficacy of amlodipine was investigated in patients with angina pectoris by means of atrial pacing during cardiac catheterization." | 3.68 | Anti-anginal efficacy of intravenous amlodipine assessed by means of atrial pacing. ( Grant, P; Gupta, S; Hillis, WS; Hogg, KJ; Hornung, RS; Singh, SP, 1991) |
| " The most frequent adverse events were visual symptoms and sinus bradycardia with ivabradine (0." | 2.73 | Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. ( Ford, I; Fox, KM; Ruzyllo, W; Tendera, M, 2007) |
| "Anginal patients who remain symptomatic despite optimally dosed beta blockade may also be given dihydropyridine calcium antagonists." | 2.69 | Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. ( Bernink, PJ; Bouwens, LH; Dunselman, PH; Herweijer, AH; Holwerda, KJ; van Kempen, LH, 1998) |
| "This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 2.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
| " From these results, the optimal dosage of amlodipine in the treatment of angina pectoris is 10 mg for the initial 3 days followed by 5 mg thereafter." | 2.68 | Clinical evaluation of serum amlodipine level in patients with angina pectoris. ( Inomata, T; Izumi, T; Miyakita, Y; Nagatomo, T; Ochiai, Y; Qu, YL; Shiba, M; Shibata, A; Washizuka, T; Watanabe, K, 1996) |
| " After two weeks, the dosage was able to be increased (according to clinical efficacy) to 10 mg of amlodipine as a single dose or 240 mg of diltiazem in four divided doses." | 2.68 | [Evaluation of amlodipine in stable effort angina. Comparison with diltiazem in terms of efficacy, tolerability and maintenance of the anti-ischemic action 24 hours after the last dose]. ( Bernaud, C; Marchand, X; Morand, P; Tibi, T, 1996) |
| "Mibefradil-treated patients showed greater decreases in heart rate and the rate-pressure product at each stage of the ETT than patients treated with amlodipine or diltiazem SR." | 2.68 | Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. ( Davies, GJ; Kobrin, I; Tzivoni, D, 1997) |
| "Treatment with amlodipine either as monotherapy or combined with other antianginal therapy for up to 26 weeks shows that efficacy is maintained, with no evidence of tolerance." | 2.67 | Amlodipine once a day in stable angina: double-blind crossover comparison with placebo. ( Cheitlin, MD; Das, SK; Deedwania, PC; Pasternak, RC; Pool, PE; Singh, JB, 1993) |
| "Amlodipine is a recently introduced, dihydropyridine with a long half life." | 2.67 | Amlodipine in patients with angina uncontrolled by atenolol. A double blind placebo controlled cross over trial. ( Channer, KS; Morice, AH; Stewart, AG; Woodmansey, PA, 1993) |
| "Amlodipine has significant anti-anginal efficacy." | 2.67 | A double-blind dose-response study of amlodipine in patients with stable angina pectoris. ( Alfiero, R; Cocco, G, 1991) |
| " About 8% of patients had a low compliance rate, irrespective of the dosage regimen." | 2.67 | [Time of drug intake in hypertension and angina pectoris. A controlled monitoring study]. ( Erne, P; Heynen, G; Saxenhofer, H; Waeber, B, 1994) |
| "The amlodipine dose was adjusted to 10 mg daily after 2 weeks if angina attacks were not abolished." | 2.67 | A 6-week double-blind comparison of amlodipine and placebo in patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy. ( Cocco, G; Fitscha, P; Klein, W; Meisner, W; Mitrovic, V; Neuss, H; Prager, G; Schlepper, M, 1991) |
| "Amlodipine was well tolerated and no patients were withdrawn due to adverse events or laboratory abnormalities." | 2.67 | A double-blind, placebo-controlled, parallel dose-response study of amlodipine in stable exertional angina pectoris. ( Cocco, G; Jackson, N; Lee, P; Taylor, SH, 1991) |
| "Mibefradil is a recently developed calcium antagonist with a unique chemical structure, pharmacologic profile, and mode of action." | 2.40 | Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris. ( Massie, BM, 1998) |
| "Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are comparable to those of conventional compounds in this series, such as nifedipine." | 2.39 | Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. ( van Zwieten, PA, 1994) |
| "Amlodipine is a dihydropyridine calcium antagonist drug with distinctive pharmacokinetic characteristics which appear to be attributable to a high degree of ionisation." | 2.38 | Clinical pharmacokinetics of amlodipine. ( Elliott, HL; Meredith, PA, 1992) |
| "Amlodipine was found to increase exercise capacity significantly and reduce electrocardiographic evidence of myocardial ischaemia after treadmill exercise testing 24 h after administration compared with placebo in patients suffering from angina pectoris." | 2.38 | A review of amlodipine in myocardial ischaemia. ( Taylor, SH, 1991) |
| "Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time." | 2.38 | The pharmacokinetic profile of amlodipine. ( Abernethy, DR, 1989) |
| "Amlodipine has also been found to be effective in reducing the anginal attack rate in patients with vasospastic angina." | 2.38 | The efficacy of amlodipine in myocardial ischemia. ( Taylor, SH, 1989) |
| "Amlodipine is a dihydropyridine calcium antagonist that has unique pharmacokinetic properties." | 2.38 | The efficacy of amlodipine in the management of ischaemic heart disease. ( McGibney, D, 1991) |
| " The impact of these agents will also be compared during irregular dosing periods." | 1.30 | Amlodipine versus diltiazem CR in the reduction of the total ischemic burden: the Circadian Anti-Ischemia Program in Europe (CAPE) II trial--clinical rationale and methodology. ( Deanfield, JE, 1998) |
| " The procedures refer to situations when detailed comparisons make sense only if the sensitivity of the trial has been shown, for example, if a dose-response relationship or a difference between active control and placebo has been established." | 1.30 | Testing strategies in multi-dose experiments including active control. ( Bauer, P; Hothorn, L; Maurer, W; Röhmel, J, 1998) |
| "Amlodipine was analysed in plasma and GCF of four patients undergoing amlodipine therapy for cardiovascular disorders, three of whom had significant gingival overgrowth." | 1.29 | Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid. ( Cholerton, S; Ellis, JS; Idle, JR; Monkman, SC; Seymour, RA; Thomason, JM, 1996) |
| "Amlodipine is a new calcium antagonist of the 1." | 1.28 | [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect]. ( Heynen, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (12.10) | 18.7374 |
| 1990's | 73 (58.87) | 18.2507 |
| 2000's | 30 (24.19) | 29.6817 |
| 2010's | 6 (4.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Halna du Fretay, X | 1 |
| Mohammed Saeed, D | 1 |
| Benamer, H | 1 |
| Bucci, C | 1 |
| Mamdani, MM | 1 |
| Juurlink, DN | 1 |
| Tu, JV | 1 |
| Weintraub, WS | 1 |
| Spertus, JA | 1 |
| Kolm, P | 1 |
| Maron, DJ | 1 |
| Zhang, Z | 1 |
| Jurkovitz, C | 1 |
| Zhang, W | 1 |
| Hartigan, PM | 1 |
| Lewis, C | 1 |
| Veledar, E | 1 |
| Bowen, J | 1 |
| Dunbar, SB | 1 |
| Deaton, C | 1 |
| Kaufman, S | 1 |
| O'Rourke, RA | 1 |
| Goeree, R | 1 |
| Barnett, PG | 1 |
| Teo, KK | 1 |
| Boden, WE | 1 |
| Mancini, GB | 1 |
| Chapman, RH | 1 |
| Yeaw, J | 1 |
| Roberts, CS | 1 |
| Goyal, RN | 1 |
| Bishnoi, S | 1 |
| Nishigaki, K | 2 |
| Inoue, Y | 1 |
| Yamanouchi, Y | 1 |
| Fukumoto, Y | 2 |
| Yasuda, S | 2 |
| Sueda, S | 1 |
| Urata, H | 1 |
| Shimokawa, H | 2 |
| Minatoguchi, S | 2 |
| Takano, H | 1 |
| Hasegawa, H | 1 |
| Narumi, H | 1 |
| Shindo, S | 1 |
| Mizuma, H | 1 |
| Kuwabara, Y | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 1 |
| Fujisawa, M | 1 |
| Yorikane, R | 1 |
| Matsuoka, Y | 1 |
| Koike, H | 1 |
| Ueno, K | 2 |
| Kalus, JS | 1 |
| White, CM | 1 |
| Pepine, CJ | 2 |
| Cooper-DeHoff, RM | 1 |
| Weiss, RJ | 2 |
| Koren, M | 1 |
| Bittar, N | 1 |
| Thadani, U | 4 |
| Minkwitz, MC | 1 |
| Michelson, EL | 1 |
| Hutchinson, HG | 1 |
| Jørgensen, B | 2 |
| Thaulow, E | 4 |
| Tepliakov, AT | 1 |
| Dzhavadova, GK | 1 |
| Akhmedov, ShD | 1 |
| Kandinskiĭ, ML | 1 |
| Vesnina, ZhV | 1 |
| Chaitman, BR | 1 |
| Parker, JO | 1 |
| Skopal, J | 1 |
| Chumakova, G | 1 |
| Kuch, J | 1 |
| Wang, W | 1 |
| Skettino, SL | 1 |
| Wolff, AA | 1 |
| Gratsianskiĭ, NA | 1 |
| Chikamori, T | 1 |
| Tomiyama, H | 1 |
| Yamashina, A | 1 |
| Zaliūnas, R | 2 |
| Brazdzionyte, J | 2 |
| Zabiela, V | 2 |
| Jurkevicius, R | 1 |
| Jurkevicus, R | 1 |
| Taylor, SH | 9 |
| Lee, P | 2 |
| Jackson, N | 2 |
| Cocco, G | 4 |
| Klein, W | 1 |
| Mitrovic, V | 1 |
| Neuss, H | 1 |
| Schlepper, M | 1 |
| Prager, G | 1 |
| Fitscha, P | 1 |
| Meisner, W | 1 |
| Bernink, PJ | 2 |
| de Weerd, P | 1 |
| ten, CF | 1 |
| Remme, WJ | 1 |
| Barth, J | 1 |
| Enthoven, R | 1 |
| Haagen, FD | 1 |
| Holwerda, NJ | 3 |
| Klomps, HC | 1 |
| Stone, PH | 1 |
| Gratsiansky, NA | 1 |
| Blokhin, A | 1 |
| Huang, IZ | 1 |
| Meng, L | 1 |
| Ikeda, J | 1 |
| Matsubara, M | 1 |
| Yao, K | 1 |
| Park, JY | 1 |
| Kim, KA | 1 |
| Park, PW | 1 |
| Lee, OJ | 1 |
| Ryu, JH | 1 |
| Lee, GH | 1 |
| Ha, MC | 1 |
| Kim, JS | 1 |
| Kang, SW | 1 |
| Lee, KR | 1 |
| Ruzyllo, W | 1 |
| Tendera, M | 1 |
| Ford, I | 1 |
| Fox, KM | 3 |
| Thacker, HP | 1 |
| Io, K | 1 |
| Ojio, S | 1 |
| Tanaka, T | 2 |
| Segawa, T | 1 |
| Matsuo, H | 1 |
| Watanabe, S | 1 |
| Hattori, A | 1 |
| Ono, H | 1 |
| Hiei, K | 1 |
| Sato, H | 1 |
| Morita, N | 1 |
| Noda, T | 1 |
| Kato, T | 1 |
| Kawasaki, M | 1 |
| Takemura, G | 1 |
| Fujiwara, H | 1 |
| Ito, A | 1 |
| Navarro Estrada, JL | 1 |
| Oliveri, R | 2 |
| Vetrovec, GW | 2 |
| Plumb, V | 2 |
| Epstein, AE | 1 |
| Kay, GN | 1 |
| Perondi, R | 1 |
| Saino, A | 1 |
| Zanchetti, A | 1 |
| Mancia, G | 1 |
| Amabile, G | 1 |
| Cellier, D | 1 |
| Guest, M | 1 |
| Bory, M | 1 |
| Ezekowitz, MD | 1 |
| Hossack, K | 1 |
| Mehta, JL | 3 |
| Weidler, DJ | 1 |
| Kostuk, W | 1 |
| Awan, N | 1 |
| Grossman, W | 1 |
| Bommer, W | 1 |
| Lehmann, G | 1 |
| Reiniger, G | 1 |
| Beyerle, A | 1 |
| Rudolph, W | 1 |
| Erne, P | 1 |
| Saxenhofer, H | 1 |
| Waeber, B | 1 |
| Heynen, G | 2 |
| Perticone, F | 1 |
| Borelli, DA | 1 |
| Pugliese, F | 1 |
| Maio, R | 1 |
| Costa, R | 1 |
| Cosco, C | 1 |
| Ceravolo, R | 1 |
| Mattioli, PL | 1 |
| Woodmansey, PA | 1 |
| Stewart, AG | 1 |
| Morice, AH | 1 |
| Channer, KS | 1 |
| Mulcahy, D | 2 |
| Purcell, H | 1 |
| Sparrow, J | 1 |
| Cunningham, D | 1 |
| Wright, C | 1 |
| Deedwania, PC | 3 |
| Cheitlin, MD | 1 |
| Das, SK | 1 |
| Pool, PE | 1 |
| Singh, JB | 2 |
| Pasternak, RC | 1 |
| Singh, S | 2 |
| Davies, RF | 1 |
| Linden, W | 1 |
| Habibi, H | 1 |
| Klinke, WP | 1 |
| Nadeau, C | 1 |
| Phaneuf, DC | 1 |
| Lepage, S | 1 |
| Dessain, P | 1 |
| Buttars, JA | 1 |
| Gaffney, M | 1 |
| Taylor, C | 1 |
| Cusenza, E | 1 |
| Haria, M | 1 |
| Wagstaff, AJ | 1 |
| Rumoroso, JR | 1 |
| Inguanzo, R | 1 |
| Cembellín, JC | 1 |
| Bodegas, A | 1 |
| Barrenetxea, JI | 1 |
| Marchand, X | 1 |
| Tibi, T | 1 |
| Bernaud, C | 1 |
| Morand, P | 1 |
| Monkman, SC | 1 |
| Ellis, JS | 1 |
| Cholerton, S | 1 |
| Thomason, JM | 1 |
| Seymour, RA | 1 |
| Idle, JR | 1 |
| Watanabe, K | 1 |
| Ochiai, Y | 1 |
| Washizuka, T | 1 |
| Inomata, T | 1 |
| Miyakita, Y | 1 |
| Shiba, M | 1 |
| Izumi, T | 1 |
| Shibata, A | 1 |
| Qu, YL | 1 |
| Nagatomo, T | 1 |
| Allan, JJ | 1 |
| Koenig, W | 1 |
| Höher, M | 1 |
| Detry, JM | 1 |
| Lopez, LM | 1 |
| van Zwieten, PA | 1 |
| Davies, GJ | 1 |
| Tzivoni, D | 2 |
| Kobrin, I | 4 |
| Charlon, V | 2 |
| Lindberg, E | 2 |
| Pordy, R | 2 |
| Kadr, H | 1 |
| Braat, S | 1 |
| Rutsch, W | 1 |
| Ramires, JA | 1 |
| Kagaya, Y | 1 |
| Ishide, N | 1 |
| Funakoshi, M | 1 |
| Hoshi, N | 1 |
| Shirato, K | 1 |
| Witkowska, M | 1 |
| Tracz, W | 1 |
| Kubler, G | 1 |
| Negrusz-Kawecka, M | 1 |
| Hlawaty, M | 1 |
| Olszowska, M | 1 |
| Salamon, P | 1 |
| Handrock, R | 1 |
| Herzig, S | 1 |
| Steffensen, R | 1 |
| Melchior, T | 1 |
| Bech, J | 1 |
| Nissen, H | 1 |
| Haastrup, B | 1 |
| Grande, P | 1 |
| Rasmussen, V | 1 |
| Hansen, JF | 1 |
| Skagen, K | 1 |
| Haghfelt, T | 1 |
| Rossinen, J | 1 |
| Partanen, J | 1 |
| Nieminen, MS | 1 |
| Bieska, G | 1 |
| Dunselman, PH | 1 |
| van Kempen, LH | 1 |
| Bouwens, LH | 1 |
| Holwerda, KJ | 2 |
| Herweijer, AH | 1 |
| Knight, CJ | 1 |
| Fujita, M | 1 |
| Nakae, I | 1 |
| Tamaki, S | 1 |
| Kihara, Y | 1 |
| Nohara, R | 1 |
| Sasayama, S | 1 |
| Massie, BM | 1 |
| Rinaldi, CA | 1 |
| Linka, AZ | 1 |
| Masani, ND | 1 |
| Avery, PG | 1 |
| Jones, E | 1 |
| Saunders, H | 1 |
| Hall, RJ | 1 |
| Bauer, P | 1 |
| Röhmel, J | 1 |
| Maurer, W | 1 |
| Hothorn, L | 1 |
| van Kesteren, HA | 1 |
| Withagen, AJ | 2 |
| Deanfield, JE | 1 |
| Frishman, WH | 1 |
| Glasser, S | 1 |
| Stone, P | 1 |
| Johnson, M | 1 |
| Fakouhi, TD | 1 |
| Klinge, R | 1 |
| Sirnes, PA | 1 |
| Hall, C | 1 |
| Van Der Vring, JA | 3 |
| Daniëls, MC | 3 |
| Withagen, PJ | 2 |
| Schelling, A | 3 |
| Cleophas, TJ | 3 |
| Hendriks, MG | 3 |
| van der Sluijs, J | 1 |
| Zwinderman, AH | 1 |
| Sanguigni, V | 1 |
| Gallù, M | 1 |
| Sciarra, L | 1 |
| Del Principe, D | 1 |
| Menichelli, A | 1 |
| Palumbo, G | 1 |
| Cannata, D | 1 |
| Strano, A | 1 |
| Hollenberg, NK | 1 |
| Williams, GH | 1 |
| Anderson, R | 1 |
| Jorgensen, B | 1 |
| Pehrsson, SK | 1 |
| Ringqvist, I | 1 |
| Ekdahl, S | 1 |
| Karlson, BW | 1 |
| Ulvenstam, G | 1 |
| Persson, S | 1 |
| Midtbø, K | 1 |
| Mølstad, P | 1 |
| Sauerbrey-Wullkopf, N | 1 |
| Kupper, W | 1 |
| Hartung, J | 1 |
| Knapp, G | 1 |
| Chugh, SK | 1 |
| Digpal, K | 1 |
| Hutchinson, T | 1 |
| McDonald, CJ | 1 |
| Miller, AJ | 1 |
| Lahiri, A | 1 |
| Martsevich, SIu | 1 |
| Sementsov, DP | 1 |
| Kutishenko, NP | 1 |
| Alimova, EV | 1 |
| Hall, R | 1 |
| Chong, C | 1 |
| Williams, C | 1 |
| DiBianco, R | 1 |
| Schoomaker, FW | 1 |
| Awan, NA | 1 |
| Bennett, T | 1 |
| Canosa, FL | 1 |
| Kawanishi, DT | 1 |
| Bamrah, VS | 1 |
| Glasser, SP | 3 |
| Barry, W | 1 |
| Meluzín, J | 1 |
| Stejfa, M | 1 |
| Novák, M | 1 |
| Zeman, K | 1 |
| Spinarová, L | 1 |
| Julínek, J | 1 |
| Toman, J | 1 |
| Simek, P | 1 |
| Kishida, H | 1 |
| Hata, N | 1 |
| Kunimi, T | 1 |
| Miyagawa, H | 1 |
| Nishiyama, H | 1 |
| Katoh, K | 1 |
| Meredith, PA | 1 |
| Elliott, HL | 1 |
| Alfiero, R | 1 |
| Pedersen, OL | 1 |
| Schroeder, P | 1 |
| Erikssen, J | 1 |
| Lund-Johansen, P | 1 |
| McGibney, D | 1 |
| Navarro Estrada, J | 1 |
| Saglietti, H | 1 |
| Dimarco, M | 1 |
| Casabé, H | 1 |
| Caponnetto, S | 1 |
| Canale, C | 1 |
| Terrachini, V | 1 |
| Masperone, MA | 1 |
| Bruzzone, F | 1 |
| Hogg, KJ | 2 |
| Hornung, RS | 2 |
| Hillis, WS | 2 |
| Gupta, S | 2 |
| Grant, P | 2 |
| Singh, SP | 2 |
| Dailey, S | 1 |
| Kay, G | 1 |
| Epstein, A | 1 |
| Silke, B | 3 |
| Verma, SP | 3 |
| Zezulka, AV | 1 |
| Sharma, S | 1 |
| Reynolds, G | 2 |
| Jackson, NC | 2 |
| Guy, S | 1 |
| Goldhammer, E | 1 |
| Sharma, SK | 2 |
| Kinnard, DR | 3 |
| Harris, M | 3 |
| Hossack, KF | 3 |
| Abernethy, DR | 1 |
| West, TW | 2 |
| Chahine, RA | 1 |
| Feldman, RL | 1 |
| Giles, TD | 1 |
| Raizner, AE | 1 |
| Nicod, P | 1 |
| Deedwania, P | 1 |
| Cheitlin, M | 1 |
| Das, S | 1 |
| Pool, P | 1 |
| Singh, J | 1 |
| Pasternak, R | 1 |
| Carabello, B | 1 |
| Doherty, J | 1 |
| Udhoji, V | 1 |
| Smith, K | 1 |
| Gorwit, J | 1 |
| Bekheit, S | 1 |
| Mather, S | 1 |
| Stein, W | 1 |
| San Fellippo, J | 1 |
| Hearan, P | 1 |
| Frais, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation[NCT00007657] | Phase 3 | 3,260 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.[NCT00825604] | Phase 2 | 0 participants (Actual) | Interventional | 2009-01-31 | Withdrawn (stopped due to Because of poor inclusion difficulties to find patient) | ||
| Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status[NCT04475094] | 75 participants (Anticipated) | Observational | 2019-12-23 | Recruiting | |||
| A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day[NCT00091429] | Phase 3 | 500 participants | Interventional | 2004-08-31 | Completed | ||
| Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention[NCT03044964] | Phase 4 | 40 participants (Anticipated) | Interventional | 2017-01-10 | Recruiting | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study[NCT02163525] | 114 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | |||
| The Trust (Treatment Results of Uterine Sparing Technologies) Study[NCT01563783] | 84 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| The LUSTOR (Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions)Trial[NCT01750008] | 51 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for amlodipine and Angor Pectoris
| Article | Year |
|---|---|
Prognostic effects of calcium channel blockers in patients with vasospastic angina--a meta-analysis.
Topics: Amlodipine; Angina Pectoris; Asian People; Calcium Channel Blockers; Coronary Vasospasm; Dihydropyri | 2010 |
Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.
Topics: Amlodipine; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Res | 2002 |
Usefulness of amlodipine for angina pectoris.
Topics: Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Cardiac Output; Clinical Trials as Topic; Dil | 1994 |
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.
Topics: Amlodipine; Angina Pectoris; Cardiovascular Diseases; Hemodynamics; Humans; Hypertension | 1995 |
Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.
Topics: Amlodipine; Angina Pectoris; Animals; Humans; Hypertension; In Vitro Techniques | 1994 |
Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Topics: Adolescent; Adult; Amlodipine; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Bloc | 1998 |
Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Clinical Tri | 1998 |
Amlodipine--a new calcium-channel blocker.
Topics: Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Humans; Hypertension | 1992 |
Clinical pharmacokinetics of amlodipine.
Topics: Absorption; Amlodipine; Angina Pectoris; Biological Availability; Calcium Channel Blockers; Drug Int | 1992 |
[Amlodipine].
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Humans; Hypertension; Nifedipine | 1991 |
[Amlodipin (Norvasc). A new calcium antagonist with long half-life].
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Half-Life; Humans; Hypertension; Nifedipine | 1991 |
The efficacy of amlodipine in the management of ischaemic heart disease.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Drug Therapy, Combination; | 1991 |
A review of amlodipine in myocardial ischaemia.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; H | 1991 |
The pharmacokinetic profile of amlodipine.
Topics: Administration, Oral; Aging; Amlodipine; Angina Pectoris; Animals; Biological Availability; Calcium | 1989 |
The efficacy of amlodipine in myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel | 1989 |
82 trials available for amlodipine and Angor Pectoris
| Article | Year |
|---|---|
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Met | 2003 |
Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study.
Topics: Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Angi | 2003 |
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Amlodipine; Angina Pectoris; Atenolol; Calcium Chan | 2004 |
Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm | 2005 |
Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Angiography; Coronary Disease; | 2005 |
A double-blind, placebo-controlled, parallel dose-response study of amlodipine in stable exertional angina pectoris.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Dose-Response Relationship, Drug | 1991 |
A 6-week double-blind comparison of amlodipine and placebo in patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel B | 1991 |
An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Diltiazem; Double-Blind Method; | 1991 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study.
Topics: Adult; Amlodipine; Angina Pectoris; Asian People; Blood Pressure; Calcium Channel Blockers; Cross-Ov | 2006 |
Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
Topics: Aged; Amlodipine; Angina Pectoris; Benzazepines; Blood Pressure; Calcium Channel Blockers; Cardioton | 2007 |
Long-term efficacy of amlodipine in patients with severe coronary artery disease.
Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Coronary Disease; Exercise Test; Female; Follow-U | 1993 |
Evaluation of the acute hemodynamic and electrophysiologic effects of intravenous amlodipine alone and in combination with a beta-blocker in patients with angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Drug Therapy, Combination; El | 1993 |
Coronary vascular reactivity and calcium antagonist therapy in patients with angina.
Topics: Amlodipine; Angina Pectoris; Blood Pressure; Coronary Circulation; Coronary Disease; Drug Evaluation | 1994 |
[Evaluation of amlodipine in stable effort angina in office cardiologic practice].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Cardiology; Female; Humans; Male; Middl | 1994 |
Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Cross-Over Studies; Double-Blind Method; | 1995 |
Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Coronary Disease; Double-Blind Method; Exe | 1993 |
[Time of drug intake in hypertension and angina pectoris. A controlled monitoring study].
Topics: Aged; Amlodipine; Angina Pectoris; Confidence Intervals; Cross-Over Studies; Female; Humans; Hyperte | 1994 |
[An ergometric cross-over evaluation of the anti-ischemic efficacy of amlodipine and gallopamil in stable angina of effort].
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Angina Pectoris; Exercise Test; Female; Gallopamil; H | 1993 |
Amlodipine in patients with angina uncontrolled by atenolol. A double blind placebo controlled cross over trial.
Topics: Aged; Amlodipine; Angina Pectoris; Atenolol; Blood Pressure; Cardiac Output; Double-Blind Method; Ex | 1993 |
Usefulness of amlodipine for angina pectoris.
Topics: Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Cardiac Output; Clinical Trials as Topic; Dil | 1994 |
Amlodipine once a day in stable angina: double-blind crossover comparison with placebo.
Topics: Aged; Amlodipine; Angina Pectoris; Double-Blind Method; Electrocardiography; Exercise Test; Fatigue; | 1993 |
Long-term double-blind evaluation of amlodipine and nadolol in patients with stable exertional angina pectoris. The Investigators of Study 152.
Topics: Adolescent; Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Double-Blind Method; Exercise | 1993 |
Relative importance of psychologic traits and severity of ischemia in causing angina during treadmill exercise. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators.
Topics: Amlodipine; Angina Pectoris; Atenolol; Exercise Test; Exercise Tolerance; Female; Humans; Male; Midd | 1993 |
Harmonic regression analysis of the effect of drug treatment on the diurnal rhythm of blood pressure and angina.
Topics: Amlodipine; Angina Pectoris; Blood Pressure; Circadian Rhythm; Double-Blind Method; Humans; Hyperten | 1993 |
Pointers from recent multicentre trials using ambulatory monitoring--placing placebo in perspective.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Coronary Disease; Drug Therapy, | 1995 |
[Evaluation of amlodipine in stable effort angina. Comparison with diltiazem in terms of efficacy, tolerability and maintenance of the anti-ischemic action 24 hours after the last dose].
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Diltiazem; Exerc | 1996 |
Clinical evaluation of serum amlodipine level in patients with angina pectoris.
Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Female; Heart Rate; Hum | 1996 |
Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blocker | 1997 |
Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient
Topics: Amlodipine; Angina Pectoris; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Patient Co | 1994 |
A double-blind evaluation of amlodipine in patients with chronic, stable angina: sustained efficacy and lack of "withdrawal phenomenon" upon abrupt discontinuation.
Topics: Amlodipine; Angina Pectoris; Double-Blind Method; Female; Humans; Male; Middle Aged; Substance Withd | 1994 |
Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blocker | 1997 |
Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Topics: Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Drug A | 1997 |
Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Double-Blind Method; Electrocardiography, | 1997 |
Loading doses of amlodipine safely increase plasma levels during the first days of treatment in patients with angina pectoris.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Female; Heart Ra | 1997 |
[Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension].
Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Drug Administration Sch | 1997 |
Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cross-Over Studi | 1997 |
Amlodipine in patients with stable angina pectoris treated with beta-blockers. Double-blind comparison with placebo.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Blood Pressure; Blood Pressure Monitoring, | 1998 |
Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Topics: Adolescent; Adult; Amlodipine; Angina Pectoris; Benzimidazoles; Blood Pressure; Calcium Channel Bloc | 1998 |
Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris | 1998 |
Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; | 1998 |
Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method | 1998 |
A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Delayed-Action P | 1998 |
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; Calcium | 1999 |
N-terminal proatrial natriuretic peptide in angina pectoris: impact of revascularization by angioplasty.
Topics: Adult; Age Factors; Aged; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Atrial Natriu | 1999 |
Anti-ischemic effects of amlodipine in patients with stable angina pectoris and myocardial ischemia during daily life. Amlodipine Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Double-Blind Method; Electr | 1999 |
Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascul
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; B | 1999 |
Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Resear
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; B | 1999 |
Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Benzimidazoles; C | 1999 |
Effect of amlodipine on exercise-induced platelet activation in patients affected by chronic stable angina.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium; Calcium Channel Blockers; Double-Blind Method; Exercise; | 1999 |
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris | 2000 |
Results and clinical implications of the CAPARES trial.
Topics: Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Angi | 2000 |
Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; | 2000 |
Amlodipine versus slow release metoprolol in the treatment of stable exertional angina pectoris (AMSA).
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Ac | 2000 |
[Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris].
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Data Interpreta | 2001 |
A randomized, double-blind comparison of the efficacy and tolerability of once-daily modified-release diltiazem capsules with once-daily amlodipine tablets in patients with stable angina.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiovascular A | 2001 |
[Effects of long-acting calcium antagonists--amlodipine and diltiazem in patients with stable angina of effort: comparative randomized controlled trial].
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; Diltiazem; Doubl | 2001 |
A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina.
Topics: Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Dela | 2001 |
Amlodipine combined with beta blockade for chronic angina: results of a multicenter, placebo-controlled, randomized double-blind study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel B | 1992 |
Amlodipine in patients with stable angina pectoris treated with nitrates and beta-blockers. The influence on exercise tolerance, systolic and diastolic functions of the left ventricle.
Topics: Amlodipine; Angina Pectoris; Diastole; Dose-Response Relationship, Drug; Drug Administration Schedul | 1992 |
Amlodipine--a new calcium-channel blocker.
Topics: Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Humans; Hypertension | 1992 |
Antianginal effects of amlodipine at a single dose on exertional angina patients using treadmill exercise testing--a randomized crossover study in comparison with placebo.
Topics: Administration, Oral; Aged; Amlodipine; Angina Pectoris; Exercise Test; Female; Hemodynamics; Humans | 1992 |
Amlodipine in post-infarction angina.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Circadian Rhythm; Female; Humans; Male; Middl | 1992 |
A double-blind dose-response study of amlodipine in patients with stable angina pectoris.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers | 1991 |
Anti-ischaemic properties of amlodipine, a new calcium antagonist, in patients with severe coronary artery disease: a prospective trial.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Exercise Test; Female; Hear | 1991 |
Open comparative study to assess the efficacy and safety of two calcium antagonists, amlodipine and diltiazem, in the treatment of symptomatic myocardial ischaemia.
Topics: Amlodipine; Angina Pectoris; Coronary Disease; Diltiazem; Hemodynamics; Humans; Middle Aged; Nifedip | 1991 |
An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiac Output; Coronary Disease; Diltiazem; | 1990 |
Amlodipine in angina pectoris: effect on maximal and submaximal exercise performance.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Exercise Test; Female; Humans; Male; Mi | 1988 |
Amlodipine--a once-daily calcium antagonist in the treatment of angina pectoris: a parallel dose-response placebo-controlled study.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Dose-Response Relationship, Drug | 1988 |
Pharmacodynamics of amlodipine: hemodynamic effects and antianginal efficacy after atrial pacing.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiac Catheterization; Cardiac Pacing, Arti | 1989 |
Clinical safety and efficacy of once-daily amlodipine for chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Drug Administration Schedule | 1989 |
Efficacy and safety of amlodipine in vasospastic angina: an interim report of a multicenter, placebo-controlled trial. The Investigators of Study 160.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Vasospasm; | 1989 |
Double-blind crossover comparison of amlodipine at three dose levels and placebo in chronic stable angina.
Topics: Aged; Amlodipine; Angina Pectoris; Chronic Disease; Double-Blind Method; Exercise Test; Female; Huma | 1989 |
A four-week double-blind, placebo-controlled, parallel dose-response study of amlodipine in patients with stable exertional angina pectoris.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Dose-R | 1989 |
Amlodipine: a once-daily calcium antagonist in the treatment of angina pectoris--a parallel dose-response, placebo-controlled study. The Amlodipine Study Group.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Dose-R | 1989 |
Amlodipine in angina pectoris: effect on maximal and submaximal exercise performance.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Exercise; Exercise Test; Female; Humans | 1989 |
Amlodipine versus nadolol in patients with stable angina pectoris.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Drug Administration Schedule; Ex | 1989 |
A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; | 1986 |
Endurance testing for evaluation of antianginal therapy with amlodipine, a calcium channel blocking agent.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Double-Blind Method; Evaluation Studies | 1988 |
Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris.
Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double | 1988 |
30 other studies available for amlodipine and Angor Pectoris
| Article | Year |
|---|---|
[Diagnosis and treatment of spastic angina revealed by cardiac arrest].
Topics: Adult; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Vasospasm; Defibrillators, Im | 2014 |
Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study.
Topics: Acute Coronary Syndrome; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Canada; Cohort | 2008 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort | 2010 |
Voltammetric determination of amlodipine besylate in human urine and pharmaceuticals.
Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Ascorbic Acid; Body Fluids; Carbon; Electrodes | 2010 |
The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
Topics: Administration, Oral; Amlodipine; Angina Pectoris; Animals; Arginine Vasopressin; Azetidinecarboxyli | 2013 |
[Reperfusion syndrome after direct myocardial revascularization on beating heart in patients with ischemic heart disease. Possibilities of prevention with amlodipine].
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Echocardiography, Doppler; Elect | 2003 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2004 |
[Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA].
Topics: Acetanilides; Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Cardiovascular Age | 2004 |
Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
Topics: Amlodipine; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 2005 |
Effects of benidipine in a rat model for experimental angina.
Topics: Amlodipine; Angina Pectoris; Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Di | 2006 |
Ivabradine: new drug. Best avoided in stable angina.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Benzazepines; Calcium Channel Bl | 2007 |
S-amlodipine--the 2007 clinical review.
Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Humans; Hypertension; Molecular Conformation; | 2007 |
Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test.
Topics: Adult; Aged; Aging; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cohort Studies; Coronary | 2007 |
Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlodipine.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiovascula | 2008 |
Emerging options in the management of myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Disease | 1994 |
Effects of amlodipine versus diltiazem on morning peak in myocardial ischemic activity in angina pectoris.
Topics: Aged; Amlodipine; Angina Pectoris; Circadian Rhythm; Diltiazem; Female; Humans; Male; Middle Aged; M | 1993 |
Amlodipine approved for hypertension, angina therapy.
Topics: Amlodipine; Angina Pectoris; Drug Approval; Humans; Hypertension; United States; United States Food | 1993 |
Left main coronary artery spasm.
Topics: Amlodipine; Angina Pectoris; Coronary Vasospasm; Diagnosis, Differential; Follow-Up Studies; Humans; | 1995 |
Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid.
Topics: Amlodipine; Angina Pectoris; Autoanalysis; Chromatography, Gas; Gingival Crevicular Fluid; Gingival | 1996 |
Amlodipine in chronic heart failure.
Topics: Amlodipine; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dru | 1997 |
[Amlodipine].
Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; He | 1998 |
Importance of alpha 1-sympathetic activity for diurnal change in ischemic threshold in patients with stable angina.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Analysis of Variance; Angina Pectoris; Calciu | 1998 |
Testing strategies in multi-dose experiments including active control.
Topics: Alkylating Agents; Amlodipine; Angina Pectoris; Animals; Calcium Channel Blockers; Controlled Clinic | 1998 |
Amlodipine versus diltiazem CR in the reduction of the total ischemic burden: the Circadian Anti-Ischemia Program in Europe (CAPE) II trial--clinical rationale and methodology.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Circadian Rhy | 1998 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
On tests of the overall treatment effect in meta-analysis with normally distributed responses.
Topics: Amlodipine; Angina Pectoris; Computer Simulation; Controlled Clinical Trials as Topic; Exercise; Hum | 2001 |
Amlodipine PREVENTS angina, not atherosclerosis.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Artery Disease; Coronary Disease; Di | 2002 |
[Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect].
Topics: Amlodipine; Angina Pectoris; Animals; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Dihyd | 1992 |
Anti-anginal efficacy of intravenous amlodipine assessed by means of atrial pacing.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiac Pacing, Artificial; Electrocardiograp | 1991 |
Haemodynamic and electrophysiological effects of amlodipine, a new long-acting calcium antagonist.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Electrocardiography; Hemodynamic | 1991 |
Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.
Topics: Adult; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Corona | 1990 |